Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile, Immunogenicity, and Preliminary Anti-tumor Activity of SYS6005 in Patients With Advanced Malignant Tumor

Next Previous
Trial Profile

A Phase I Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile, Immunogenicity, and Preliminary Anti-tumor Activity of SYS6005 in Patients With Advanced Malignant Tumor

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 22 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs SYS 6005 (Primary)
  • Indications Adrenal cancer; Advanced breast cancer; Bladder cancer; Cholangiocarcinoma; Chronic lymphocytic leukaemia; Colon cancer; Diffuse large B cell lymphoma; Follicular lymphoma; Gastric cancer; Gynaecological cancer; Hodgkin's disease; Lung cancer; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma; Oesophageal cancer; Pancreatic cancer; Prostate cancer; Renal cancer; Skin cancer; Solid tumours; Testicular cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors CSPC Pharmaceutical Group

Most Recent Events

  • 09 May 2025 Status changed from not yet recruiting to recruiting.
  • 15 Apr 2025 According to a Radiance Biopharma media release, company announced that the first patient in China has been dosed in this Phase 1 clinical trial.
  • 01 Apr 2025 According to a Radiance Biopharma media release, company announced that the IND supports the initiation of a Phase 1 dose escalation and expansion clinical trial of RB-164 in patients with ROR-1 positive hematologic and solid cancers in the United States of America.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top